Search Result

Results for "

Tie2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Tie (31) Akt (3) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (7) Autophagy (3) Bacterial (1) Bcr-Abl (2) c-Fms (1) c-Kit (3) c-Met/HGFR (6) Cadherin (2) Claudin (2) Discoidin Domain Receptor (1) EGFR (1) Ephrin Receptor (1) ERK (2) FGFR (3) FLT3 (6) Fungal (1) Insulin Receptor (2) MAP3K (1) MEK (1) p38 MAPK (2) PDGFR (2) Phosphatase (3) PI3K (2) Raf (1) Ras (1) Reference Standards (5) Ser/Thr Kinase (2) Src (3) TAM Receptor (4) Trk Receptor (2) Tyrosinase (1) VEGFR (23)
By Research Areas:	Cancer (37) Cardiovascular Disease (12) Infection (4) Inflammation/Immunology (7) Metabolic Disease (1)

By Targets:

Tie (31)

Akt (3)

Anaplastic lymphoma kinase (ALK) (2)

Apoptosis (7)

Autophagy (3)

Bacterial (1)

Bcr-Abl (2)

c-Fms (1)

c-Kit (3)

c-Met/HGFR (6)

Cadherin (2)

Claudin (2)

Discoidin Domain Receptor (1)

EGFR (1)

Ephrin Receptor (1)

ERK (2)

FGFR (3)

FLT3 (6)

Fungal (1)

Insulin Receptor (2)

MAP3K (1)

MEK (1)

p38 MAPK (2)

PDGFR (2)

Phosphatase (3)

PI3K (2)

Raf (1)

Ras (1)

Reference Standards (5)

Ser/Thr Kinase (2)

Src (3)

TAM Receptor (4)

Trk Receptor (2)

Tyrosinase (1)

VEGFR (23)

By Research Areas:

Cancer (37)

Cardiovascular Disease (12)

Infection (4)

Inflammation/Immunology (7)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Tie

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13016

Cabozantinib Maximum Cited Publications 57 Publications Verification XL184; BMS-907351	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, *TIE2, and FLT3* (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-13024

Rebastinib 10+ Cited Publications DCC-2036	Bcr-Abl FLT3 Src Apoptosis	Cancer
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1 ^WT and Abl1 ^T315I with IC₅₀s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.

HY-16782

Pexmetinib 2 Publications Verification ARRY-614	Tie p38 MAPK Autophagy	Cancer
Pexmetinib is a potent *Tie-2* and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-109041

Razuprotafib 4 Publications Verification AKB-9778	Phosphatase Tie	Inflammation/Immunology
Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

HY-16135

CEP-11981 ESK981; BOL 303213X	VEGFR FGFR	Cancer
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects .

HY-100556

Tie2 kinase inhibitor 1 1 Publications Verification	Tie	Cancer
Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC₅₀ of 250 nM . Tie2 kinase inhibitor 1 has anti-cancer activity .

HY-16025

EOC317 1 Publications Verification ACTB-1003	FGFR VEGFR	Cancer
EOC317 (ACTB-1003) is an oral kinase inhibitor with IC₅₀s of 6, 2 and 4 nM for FGFR1, VEGFR2 and *Tie-2*.

HY-12014

SU11274 5+ Cited Publications PKI-SU11274	c-Met/HGFR Autophagy Apoptosis	Cancer
SU11274 is a selective Met inhibitor with IC₅₀ of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

HY-100756

BAY-826 1 Publications Verification	Discoidin Domain Receptor Tie	Cancer
BAY-826, a chemical probe, is a selective and potent *TIE-2* inhibitor with a K_d of 1.6 nM, respectively.

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, *TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3* respectively.

HY-113571

Tie2 kinase inhibitor 2	Tie	Cardiovascular Disease
Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor with an IC₅₀ value of 1 μM. Tie2 kinase inhibitor 2 inhibits endothelial cell tube formation, and can be used for Tie2-mediated angiogenic disorders research .

HY-P10580

Vasculotide	Tie PI3K Akt Cadherin Claudin	Cardiovascular Disease Infection Inflammation/Immunology
Vasculotide is a blood-brain barrier (BBB)-penetrant *Tie2* agonist. Vasculotide binds to a unique domain of *Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt* and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide with antibiotics reduces lung injury .

HY-P3369

Gersizangitide AXT-107	VEGFR Tie Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Gersizangitide (AXT107) is an anti-angiogenic peptide consisting of 20 amino acids, derived from collagen IV. Gersizangitide is an inhibitor of VEGF-A and VEGF-C and an activator of *Tie2. Gersizangitide can block VEGF* receptor signaling, inhibit vascular leakage, neovascularization and inflammation. Gersizangitide can be used in the research of diseases related to ocular neovascularization and angiogenesis .

HY-108333

SB-633825 4 Publications Verification	Ser/Thr Kinase	Cardiovascular Disease Cancer
SB-633825 is a potent and ATP-competitive inhibitor of *TIE2, LOK (STK10)* and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N2666

5α-Hydroxycostic acid	VEGFR	Cancer
5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and *Ang2/Tie2* pathways .

HY-P10580A

Vasculotide TFA	Cadherin Tie Claudin PI3K Akt	Cardiovascular Disease Infection Inflammation/Immunology
Vasculotide TFA is a blood-brain barrier (BBB)-penetrant *Tie2* agonist. Vasculotide TFA binds to a unique domain of *Tie2, induces receptor clustering to drive phosphorylation, activates downstream PI3K/Akt* and eNOS pathways, enhances inter-endothelial cell junctions (such as VE-cadherin and claudin-5), and inhibits inflammatory adhesion molecules, ultimately stabilizing the vascular endothelial barrier and reducing its permeability . Vasculotide TFA alleviates pulmonary microvascular leakage and microcirculatory dysfunction caused by cardiopulmonary bypass, acts as an adjuvant radioprotective agent to reduce acute radiation dermatitis, and promotes BBB recovery after focused ultrasound (FUS). Combination of Vasculotide TFA with antibiotics reduces lung injury .

HY-13016R

Cabozantinib (Standard) XL184 (Standard); BMS-907351 (Standard)	Reference Standards VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, *TIE2, and FLT3* (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-160708

Tie2 kinase inhibitor 3	Tie	Cancer
Tie2 kinase inhibitor 3 (compound 63) is a potent *Tie-2* kinase inhibitor with good oral activity (IC₅₀=30 nM). Tie2 kinase inhibitor 3 inhibits phosphorylation and signaling of *Tie-2* by competing with the ATP binding site of *Tie-2* kinase. This inhibition affects the stability and maturity of blood vessels, which has an impact on tumor angiogenesis. Tie2 kinase inhibitor 3 can be used to restrict tumor growth and regulate angiogenesis .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, *Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

HY-13016A

Cabozantinib hydrochloride XL184 hydrochloride; BMS-907351 hydrochloride	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, *TIE2, and FLT3* (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis .

HY-100556R

Tie2 kinase inhibitor 1 (Standard)	Tie Reference Standards	Cancer
Tie2 kinase inhibitor 1 (Standard) is the analytical standard of Tie2 kinase inhibitor 1 (HY-100556). This product is intended for research and analytical applications. Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM . Tie2 kinase inhibitor 1 has anti-cancer activity .

HY-13023

AMG-Tie2-1	VEGFR	Cancer
AMG-Tie2-1 is an inhibitor of tunica interna endothelial cell kinase 2 (Tie2) with an IC₅₀ of 1 nM. AMG-Tie2-1 is a VEGFR2 inhibitor with an IC₅₀ of 3 nM .

HY-112423

CE-245677	Trk Receptor Tie	Cardiovascular Disease Cancer
CE-245677 is a potent reversible inhibitor of *Tie2* and TrkA/B kinases with a cellular IC₅₀s of 4.7 and 1 nM.

HY-107144

LY2457546	Tyrosinase Ephrin Receptor VEGFR PDGFR FLT3 Tie	Cancer
LY2457546 is a potent and orally active multi-targeted anti-angiogenic tyrosine kinases inhibitor. LY2457546 demonstrates potent activity against targets that include VEGFR2, PDGFRβ, FLT-3, *Tie-2* and members of the Eph family of receptors. LY2457546 can be used for the research of cancer, such as leukemia .

HY-118105

RK-20448	Src VEGFR Tie	Infection Cancer
RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R and *Tie-2* with IC₅₀ values of 0.24, 1.19, 10.74 and 5.85 µM, respectively. RK-20448 also inhibits BLK, Csk, Fyn and Lyn with IC₅₀ values of 0.37, 4.27, 2.03 and 0.43 µM, respectively. RK-20448 is the cis isomer of A-419259 (HY-15764) .

HY-N3634

Corylifol C	EGFR TAM Receptor Tie	Cancer
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-16782R

Pexmetinib (Standard) ARRY-614 (Standard)	Tie p38 MAPK Autophagy Reference Standards	Cancer
Pexmetinib (Standard) is the analytical standard of Pexmetinib. This product is intended for research and analytical applications. Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-15973

BSF-466895 A-422885.66	Tie	Cancer
BSF-466895(A-422885.66) is a *Tie2* inhibitor with an IC₅₀ of 5 nM and it can also inhibit Tie1 .

HY-125741

GW768505A free base	Tie VEGFR	Cancer
GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and *Tie-2*, with a pIC₅₀ of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity .

HY-12572

TIE-2/VEGFR-2 kinase-IN-2	Tie VEGFR	Cancer
TIE-2/VEGFR-2 kinase-IN-2 is a potent dual VEGFR2 and *Tie-2* inhibitor with pIC₅₀ values of 8.61 and 8.56, respectively . TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research .

HY-112294

TIE-2/VEGFR-2 kinase-IN-1	Tie VEGFR	Cardiovascular Disease Inflammation/Immunology Cancer
TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis .

HY-156635

TIE-2/VEGFR-2 kinase-IN-3	Tie VEGFR	Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent *TIE-2* and VEGFR-2 tyrosine kinase receptors inhibitors with IC₅₀ values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis .

HY-156637

TIE-2/VEGFR-2 kinase-IN-4	Tie VEGFR	Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent *TIE-2* and VEGFR-2 tyrosine kinase receptors inhibitors with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis .

HY-100824

PP2 Analog	Src	Cancer
PP2 Analog (compound 3) is a ATP-competitive Src family kinases inhibitor with the IC₅₀ values of 0.22, 0.15, 2.68, and 7 aganist of lck (64-509), src , kdr, and tie-2 .

HY-156638

TIE-2/VEGFR-2 kinase-IN-5	Tie VEGFR	Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. TIE-2/VEGFR-2 kinase-IN-5 also is a potent *TIE-2* and VEGFR-2 tyrosine kinase inhibitor with pIC₅₀ values of 7.78 nM and 8.11 nM, respectively. TIE-2/VEGFR-2 kinase-IN-5 can be used for the research of angiogenesis .

HY-16135A

CEP-11981 tosylate ESK981 tosylate; BOL 303213X tosylate	VEGFR FGFR	Others Cancer
CEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects .

HY-14243

CEP-14083	Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie	Cancer
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC₅₀ value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma .

HY-164529

SJ-C1044	Raf Ras MEK ERK VEGFR Tie c-Fms	Cancer
SJ-C1044 is an orally available pan-RAF inhibitor with immunomodulatory and anti-tumor activities. SJ-C1044 inhibits wild-type BRAF, wild-type CRAF, and BRAF (V600E) with IC₅₀ values ??of 331, 257, and 187 nM, respectively. SJ-C1044 inhibits tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. In addition, SJ-C1044 also has a certain inhibitory effect on VEGFR2, *TIE2, and CSF1R, with IC₅₀* values ??of 100, 23, and 235 nM, respectively. SJ-C1044 improves the tumor immune microenvironment by inhibiting angiogenesis and regulating macrophage function. SJ-C1044 can be used in the study of colorectal cancer .

HY-123565

TP-S1-68	Tie Fungal Bacterial	Infection Cancer
TP-S1-68 (Compound 10) is a *TIE-2* inhibitor with an IC₅₀ of 3.65 μM. TP-S1-68 exhibits antibacterial activity against a variety of fungal and bacteria. TP-S1-68 serves as a starting compound for the further development of *TIE-2* inhibitors. TP-S1-68 can be used in research related to solid tumors, bacterial infections and fungal infections .

HY-109041A

Razuprotafib sodium AKB-9778 sodium	Phosphatase Tie	Inflammation/Immunology
Razuprotafib (AKB-9778) sodium is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib sodium promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib sodium inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib sodium shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

HY-109041R

Razuprotafib (Standard) AKB-9778 (Standard)	Reference Standards Phosphatase Tie	Inflammation/Immunology
Razuprotafib (Standard) is the analytical standard of Razuprotafib (HY-109041). This product is intended for research and analytical applications. Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

HY-N17788

6-Hydroxy-2,2′,4,4′-tetrabromodiphenyl ether	Tie	Cancer
6-Hydroxy-2,2′,4,4′-tetrabromodiphenyl ether is a selective inhibitor of *Tie2* kinase, with an IC₅₀ value of 2.1 μM. 6-Hydroxy-2,2′,4,4′-tetrabromodiphenyl ether interacts with the ATP binding site of Tie2 kinase, inhibiting kinase activity and subsequently blocking tumor angiogenesis. 6-Hydroxy-2,2′,4,4′-tetrabromodiphenyl ether can be isolated from sponges of the genus Dysidea .

HY-P992323

BI-836880	VEGFR Tie ERK	Cardiovascular Disease Cancer
BI-836880 is a humanized bispecific nanobody and a selective inhibitor of VEGF and ANG2, with a K_d of 16 pM for hANG2, an EC₅₀ of 1.4 nM for VEGF₁₆₅, and an EC₅₀ of 2.3 nM for VEGF₁₂₁. BI-836880 blocks ERK phosphorylation downstream of VEGF-A as well as *TIE2* phosphorylation downstream of ANG2. BI-836880 does not inhibit ANG1-mediated TIE2 phosphorylation. BI-836880 exerts anti-angiogenic effects, reduces the number of immature endothelial vessels in tumor tissues, and inhibits tumor growth in preclinical models. BI-836880 can be used in the research of pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, colon cancer, and Lewis lung cancer .

HY-108333R

SB-633825 (Standard)	Ser/Thr Kinase Reference Standards	Cardiovascular Disease Cancer
SB-633825 (Standard) is the analytical standard of SB-633825 (HY-108333). This product is intended for research and analytical applications. SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .

HY-111277

CEP-14513	Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie MAP3K Apoptosis	Cancer
CEP-14513 is an ALK inhibitor with an IC₅₀ of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, *TIE2* and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma .

HY-117733

Zerumin A	Tie VEGFR	Cancer
Zerumin A is an anti-angiogenic agent that acts on multiple molecular targets related to angiogenesis (including kdr/VEGFR2, angpt1, angpt2, tie1, and *tie2). Zerumin A specifically inhibits* the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by regulating the VEGF-VEGFR and ANGPT-TIE signaling pathways, and dose-dependently inhibits angiogenesis (10-20 μM significantly inhibits zebrafish embryo angiogenesis). Zerumin A can be used in the research of cancer and angiogenesis-related inflammatory diseases. Zerumin A can be naturally extracted from the 95% ethanol extract of the fruits, seeds, and pericarp of Alpinia caerulea (R.Br.) Bentham (a plant of the Alpinia genus in the Zingiberaceae family) .

Cat. No.	상품명	Target	Research Area